What does Prelude Therapeutics Incorporated do?
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF),…
What is Prelude Therapeutics Incorporated's P/E and P/B ratio?
Prelude Therapeutics Incorporated has a P/E ratio of -4.7 and a P/B ratio of 2.15.
What is Prelude Therapeutics Incorporated's debt-to-equity ratio?
Prelude Therapeutics Incorporated has a debt-to-equity ratio of 0.13.
How much does Prelude Therapeutics Incorporated owe compared with what it owns?
Prelude Therapeutics Incorporated owes $0.29 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Prelude Therapeutics Incorporated's Positivity rank?
Prelude Therapeutics Incorporated is ranked #3,278 of 6,774 companies globally and #1,353 of 4,000 in United States on PositoAI, with a Positivity Score of 20,704.
Does Prelude Therapeutics Incorporated have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Prelude Therapeutics Incorporated.
Where can I read the latest news about Prelude Therapeutics Incorporated?
Recent headlines about Prelude Therapeutics Incorporated from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Prelude Therapeutics Incorporated have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Prelude Therapeutics Incorporated's current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.